Complement degradation product C3d in urine: Marker of lupus nephritis

Journal of Rheumatology

Volumn 27, Issue 2, 2000, Pages 380-383

  Negi, Veer Singh ^a   Aggarwal, Amita ^a   Dayal, Rajeshwar ^a   Naik, Sita ^a   Misra, Ramnath ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

C3d; Disease Activity; Elisa; Systemic Lupus Erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3D;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; URINE LEVEL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; COMPLEMENT C3D; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE;

EID: 0033975466     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Vaughan JH, Bayles TB, Savour CB. The response of serum gamma globulin level and complement titre to ACTH therapy in lupus erythematosus disseminatosus. J Lab Clin Med 1961; 37:698-702.
2. Lim KL, Jones AC, Brown NS, Powell RJ. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4 and C3 degration products. Ann Rheum Dis 1993;52:429-35.
3. Lloyd W, Schur PH. Immune complexes, complement and anti DNA antibodies in exacerbation of SLE. Medicine 1981;60:208-17.
4. Fielder AHL, Walport MJ, Batchelor JR, et al. Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. BMJ 1983;286:425-8.
5. Krauldat PB, Krapf B, Manger B, Kalden JR. Evaluation of plasma C3d and immune complex determination in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus and spondylitis ancylopoietica. Rheumatol Int 1985;5:97-101.
6. Rother E, Lang B, Coldeway R, Hartung K, Peter HH. Complement split product C3d as indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 1993;12:31-5.
7. Swaak AJ, Rooyen AV, Vogelar C, Pillay M, Hack E. Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course. Rheumatol Int 1986;6:221-6.
8. Sacks SH, Wudding Z, Peter AA, Barrie H. Endogenous complement C3 in immune complex nephritis. Lancet 1993;342:1273-4.
9. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
11. Pirani CL, Pollock VE. Systemic lupus erythematosus glomerulonephritis (lupus nephritis). In: Cluskey RT, Andres GA, editors. Immunologically mediated renal disease. New York: Marcel Dekker; 1978.
12. Mollness TE. Quantification of the C3d split products of human complement by a sensitive enzyme linked immunosorbent assay. Scand J Immunol 1985;21:607-13.
13. Wan KC, Lewis HP. C3d levels in normal individuals of Chinese origin. Br J Biomed Sci 1993;50:8-12.
14. Peakman M, Lobo-Yeo A, Senaldi G, Tee DEH, Vergani D. Quantification of C3d in biological fluids by an enzyme linked immunosorbent assay. J Immunol Methods 1987;104:51-6.
15. Kelly RH, Carpenter AB, Sudol KS, Jugariapudi SP, Manzi S. Complement C3 fragments in urine detection in systemic lupus erythematosus patients by Western blotting. Appl Theor Electrophor 1993;3:265-9.
16. Manzi S, Joan E, Raisie A, et al. Sensitivity and specifity of plasma and urine complement split products as indicators of lupus activity. Arthritis Rheum 1996;39:1178-88.
17. Swaak AJ, Groenwold J, Hannema H, Hack CE. Correlation of disease activity with circulating immune complexes (C1qba) and complement breakdown products (C3d) in patients with systemic lupus erythematosus. A prospective study. Rheumatol Int 1985;5:215-20.